Next Article in Journal
Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography
Previous Article in Journal
Association of Lower Plasma Homoarginine Concentrations with Greater Risk of All-Cause Mortality in the Community: The Framingham Offspring Study
Previous Article in Special Issue
Exposure to Aggregatibacter Actinomycetemcomitans before Symptom Onset and the Risk of Evolving to Rheumatoid Arthritis
Open AccessArticle

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis

1
Rheumatology Centre, Toulouse University Hospital and University Toulouse III Paul Sabatier, 31059 Toulouse, France
2
Rheumatology Division, University of Colorado, Denver, CO 80111, USA
3
Department of Rheumatology & Immunology, Brigham and Women’s Hospital, Boston, MA 02115, USA
4
Department of Internal Medicine, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX 75231, USA
5
Immunology, Bristol-Myers Squibb, Princeton, NJ 08540, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 2017; https://doi.org/10.3390/jcm9062017
Received: 20 May 2020 / Revised: 10 June 2020 / Accepted: 22 June 2020 / Published: 26 June 2020
(This article belongs to the Special Issue Rheumatoid Arthritis: Pathogenesis, Diagnosis and Therapies)
To date, the impact of background glucocorticoids (GC) on the efficacy and safety of abatacept or adalimumab in patients with active rheumatoid arthritis (RA) is not clearly established. This post hoc analysis of (AMPLE) trial (NCT00929864) compared efficacy and safety outcomes over 2 years in patients treated with abatacept or adalimumab plus background methotrexate (MTX), who continued GC (≤10 mg/day) versus those who were not receiving GC (no-GC). Of 646 randomized patients, 317 received abatacept + MTX (161 GC, 156 no-GC) and 326 received adalimumab + MTX (162 GC, 164 no-GC). At Year 2, the adjusted mean changes from baseline in Disease Activity Score (DAS28 C-reactive protein (CRP)) and Health Assessment Questionnaire-Disability Index (HAQ-DI) were not significantly different in the GC versus no-GC subgroups receiving abatacept or adalimumab. A similar proportion of patients achieved remission, HAQ-DI score improvement ≥0.3 and radiographic progression rates. No clinically meaningful safety differences were observed between GC versus no-GC subgroups either with abatacept or adalimumab. In patients with active RA of similar baseline disease activity treated with abatacept or adalimumab plus background MTX, there was no additional value of background GC on clinical, functional or radiographic outcomes over two years. View Full-Text
Keywords: disease activity; rheumatoid arthritis; biologic DMARDs disease activity; rheumatoid arthritis; biologic DMARDs
Show Figures

Figure 1

MDPI and ACS Style

Degboé, Y.; Schiff, M.; Weinblatt, M.; Fleischmann, R.; Ahmad, H.A.; Constantin, A. Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. J. Clin. Med. 2020, 9, 2017.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop